Objective: The purpose of this study is to determine the relationship and role of CYP17A1 gene expression to androgen biosynthesis activity in prostate cancer patients. Material & Methods: The samples of this study are patients diagnosed with prostate adenocarcinoma based on histopathology examination who underwent TURP surgery at Sardjito General Hospital. A total of 30 samples were examined for PCR to determine the presence and absence of CYP17A1 gene expression. CYP17A1 gene expression was analyzed with the patient’s age, stage, organ metastasis, Gleason score, and PSA value. Results: Analysed using Chi-Square Tests, p=0.784 was obtained on expression of CYP17A1 gene with patient’s age, p=0.469 on expression of CYP17A1 gene with staging tumor, p=0.855 on expression of CYP17A1 gene with presence or absence of organ metastasis, p=0.059 on expression of CYP17A1 gene expression with total Gleason score, p=0.895 on expression of CYP17A1 gene with PSA value. Conclusion: There was no association between CYP17A1 gene expression and intratumoral androgen biosynthesis activity based on the patient’s age, patient’s clinical stage, organ metastasis, Gleason score, and PSA value.
androgen, prostate cancer, CYP17A1, metastasis, Gleason score, PSA
Ferlay, J., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359.
Abouassaly R., Thompson IM., Platz EA,. Klein EA. Epidemiology, etiology, and prevention of prostate cancer, dalam Campbell-Walsh Urology tenth edition (Wein A.J., Kavoussi L.R., Novick A.C., Partin A.W., Peters A.C., eds). Saunders Elsevier: Philadelphia. 2012; 2704-2725.
Wu CP, Gu FL. The prostate in eunuchs. Prog Clin Biol Res. 1991; 370: 249–55.
Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, et al. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology. 1999; 54: 1112–9.
Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997; 57: 4511–6.
Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007; 25: 1596–605.
Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab. 2004; 89: 2434–41.
Payne, A. H., Hales, D. B. Overview of Steroidogenic Enzymes in the Pathway from Cholesterol to Active Steroid Hormones.Endorc Rev. 2004; 25(6): 947-70.
Bonomo S, Hansen CH, Petrunak EM, Scott EE, Styrishave B, Jørgensen FS, Olsen L. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. Scientific Reports. 2016; 6: 29468.